Status:
COMPLETED
Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
This is an open label, single-centered treatment protocol designed to monitor the safety of patients treated with a 200 mg daily dose of CASODEX. Patient will receive CASODEX as long as physician feel...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed adenocarcinoma of the prostate gland
- Patients with advanced prostate cancer
- Adult male over the age of 18 years old
- Normal liver function (AST \< 2 x Upper Limit Normal)
Exclusion
- ECOG performance status of 4.
- Previous history or presence of another malignancy other than prostate cancer or treated squamous/basal cell carcinoma of the skin, within the last 5 years.
Key Trial Info
Start Date :
December 1 1994
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
101 Patients enrolled
Trial Details
Trial ID
NCT00846976
Start Date
December 1 1994
End Date
June 1 2013
Last Update
January 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
New York, New York, United States